Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 38%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is a strong investment opportunity due to its leadership position in the growing automated insulin delivery market, its solid financial performance with plans for continued growth and profitability, and its commitment to innovation through ongoing R&D investments. While there are some challenges, such as potential supply chain disruptions and competition in the market, Insulet's differentiated product and global reach position it well for long-term success. With potential upside risks from faster adoption and execution in key areas, and a fair valuation based on EV/Sales and EV/EBITDA multiples, a positive outlook on this stock is supported.

Bears say

Insulet is facing a number of headwinds, including market risks and global inflationary trends, competition from other companies in the diabetes market, potential intellectual property challenges and patent litigation, and shifts in government regulations and reimbursement policies. In addition, the company's recent downward revision in its sales outlook has raised concerns about its ability to maintain growth and profitability in the future. These factors, coupled with uncertainty surrounding management's plans and potential competition in the patch pump market, warrant a negative outlook for Insulet's stock.

Insulet (PODD) has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 21 analysts, Insulet (PODD) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $193.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $193.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.